ArticleInternational journal of clinical rheumatology2010
Management of cardiovascular complications in systemic lupus erythematosus.
Article in International journal of clinical rheumatology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04046172 (Treatment of Periodontal Disease in Systemic Lupus Erytematosus), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment of Periodontal Disease in Systemic Lupus Erytematosus: A Pilot Randomized Controlled Clinical Trial
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Saudi National Clinical Practice Guidelines for Management of Adult Systemic Lupus Erythematosus.Current rheumatology reviews · 2025Guideline
- Article
- Prevalence of major adverse cardiovascular events among Saudi patients with systemic lupus erythematosus compared with the general population: updates from the national SLE and PURE cohorts.Lupus science & medicine · 2024Article
- Exploring cardiovascular implications in systemic lupus erythematosus: A holistic analysis of complications, diagnostic criteria, and therapeutic modalities, encompassing pharmacological and adjuvant approaches.Biomolecular concepts · 2024Review
- Proposal of a novel cardiovascular risk prediction score in lupus nephritis.Frontiers in immunology · 2024Article
- Review
- Coronary Microvascular Dysfunction in Patients With Systemic Lupus Erythematosus and Chest Pain.Frontiers in cardiovascular medicine · 2022Review
- Review
- Understanding Accelerated Atherosclerosis in Systemic Lupus Erythematosus: Toward Better Treatment and Prevention.Inflammation · 2021Review
- Treatment Outcomes of Proliferative vs. Non-proliferative Adult Lupus Nephritis: A 10-Year Follow-Up.Cureus · 2021Article
- Corticosteroid dosing and opioid use are high in patients with SLE and remain elevated after belimumab initiation: a retrospective claims database analysis.Lupus science & medicine · 2020Article
- Management of cardiovascular disease in patients with systemic lupus erythematosus.Expert opinion on pharmacotherapy · 2020Review
- The economic burden of systemic lupus erythematosus in commercially- and medicaid-insured populations in the United States.Seminars in arthritis and rheumatism · 2020Observational
- Ganglionic Acetylcholine Receptor Antibodies and Autonomic Dysfunction in Autoimmune Rheumatic Diseases.International journal of molecular sciences · 2020Review
- Cardiovascular risk profiles in a lupus cohort: what do different calculators tell us?Lupus science & medicine · 2017Article
- The prevalence and burden of systemic lupus erythematosus in a medicare population: retrospective analysis of medicare claims.Cost effectiveness and resource allocation : C/E · 2015Article
- Obesity and cytokines in childhood-onset systemic lupus erythematosus.Journal of immunology research · 2014Article
- Adverse pregnancy outcomes and subsequent risk of cardiovascular disease in women with systemic lupus erythematosus.Lupus science & medicine · 2014Article
- Relation of carotid intima-media thickness and plaque with incident cardiovascular events in women with systemic lupus erythematosus.The American journal of cardiology · 2013Article
- Risk factors in cardiovascular disease in systemic lupus erythematosus.Current cardiology reviews · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cardiovascular disease (CVD) is a major cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE). Patients with SLE have an excess risk compared with the general population; this is particularly pronounced in younger women with SLE who have an excess risk of over 50-fold compared with population controls. There is a higher prevalence of subclinical atherosclerosis in patients with SLE compared with controls, as demonstrated by a variety of imaging modalities discussed in this review. The causality of the excess risk of CVD and subclinical atherosclerosis is multifactorial in patients with SLE. While traditional risk factors play a role, after controlling for the traditional Framingham risk factors, the excess risk is still 7.5-fold greater than the general population. This review will also cover novel cardiovascular risk factors and some SLE-specific variables that contribute to CVD risk. This review discusses the risk factor modification and the evidence available for treatment of these risk factors in SLE. There have not yet been any published randomized, controlled trials in patients with SLE with respect to CVD risk factor modifications. Thus, the treatment and management recommendations are based largely on published guidelines for other populations at high risk for CVD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.